BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37393217)

  • 1.
    van der Aa DC; Gisbertz SS; Anderegg MCJ; Lagarde SM; Klaassen R; Meijer SL; van Dieren S; Hulshof M; Bergman J; Bennink RJ; van Laarhoven HWM; van Berge Henegouwen MI
    J Gastrointest Cancer; 2024 Mar; 55(1):270-280. PubMed ID: 37393217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
    Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction.
    Gabrielson S; Sanchez-Crespo A; Klevebro F; Axelsson R; Albert Tsai J; Johansson O; Nilsson M
    Acta Radiol; 2019 May; 60(5):578-585. PubMed ID: 30111193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study.
    Hagen PV; Heijl MV; van Berge Henegouwen MI; Boellaard R; Bossuyt PM; Kate FJ; Dekken HV; Hoekstra OS; Sloof GW; Lanschot JJ
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
    Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG PET using SUV
    Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
    BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
    J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
    Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of
    Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
    J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review.
    Zemanová M; Obermannová R; Haruštiak T
    Klin Onkol; 2021; 34(2):113-119. PubMed ID: 33906359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
    Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
    J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.